Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $28.8 million, representing a 41% increase year-over-year, while total revenue for fiscal 2025 was $88.5 million, up 24% from the previous year [13] - Lung diagnostics revenue reached $25.1 million in Q4 2025, a 46% increase, and $79.2 million for the fiscal year, a 22% increase [13] - Adjusted EBITDA for Q4 was positive at $530,000, marking the first positive quarter for the company, and a loss of $17.5 million for the year, an improvement of 21% over 2024 [17] Business Line Data and Key Metrics Changes - Lung diagnostics test volumes were 18,000 in Q4, a 23% increase, and 62,600 for the fiscal year, a 15% increase [13] - Development services revenue was $3.6 million for Q4, a 12% increase, and $9.3 million for the fiscal year, a 41% increase [14] Market Data and Key Metrics Changes - Volumes from primary care accounted for 12% of total Nodify tests in Q4, growing 67% year-over-year, while volumes from pulmonology grew 26% [6][7] - The company ended Q4 with $19.0 million in unrestricted cash, a 14% increase over Q3, and pro forma cash and cash equivalents of $33.7 million [18] Company Strategy and Development Direction - The company is focused on three main goals for 2025 and 2026: growing top-line revenue, improving organizational effectiveness, and advancing its pipeline for future growth [3] - A three-tiered commercial strategy has been implemented to enhance lung nodule management through the use of Nodify Lung testing [4][6] - The company plans to add approximately 6 sales representatives per quarter in 2026 to drive growth through increased market penetration [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute against significant long-term opportunities, emphasizing operational discipline and capital efficiency [21][22] - Guidance for 2026 anticipates annual revenue between $106 million and $112 million, representing a 23% growth over 2025 [19] Other Important Information - The company achieved a gross margin of 83% in Q4, an improvement of 400 basis points, and expects margins to remain near 80% throughout 2026 [15] - The company has announced partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories to develop and validate tests [8][9] Q&A Session Summary Question: Expected revenue and volume step down in Q1 - Management acknowledged weather disruptions and noted that Q1 typically sees a step down in average selling price and volume, consistent with historical seasonality [26][27] Question: Pipeline developments and future tests - Management indicated that no new tests are planned for commercialization within the next 12 months, focusing instead on ensuring positive reimbursement positions [30] Question: Primary care sales rep productivity - The primary care focus has grown to 12% of total Nodify orders, with expectations for continued growth as the sales team matures [32][33] Question: Cash position and need for additional cushion - Management expressed confidence in the cash position, strengthened by operational improvements and additional cash raised through at-the-market proceeds [41] Question: Evidence of shifting stage in lung cancer diagnosis - Management encouraged physicians to publish data on the positive impact of Nodify testing, emphasizing the importance of awareness and compliance [46] Question: Updates on clinical studies and data readouts - Management plans to continue submitting abstracts and papers for real-world data from the CLARIFY study, with the earliest data from the ALTITUDE study expected in 2027 [53]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $28.8 million, representing a 41% increase year-over-year, while total revenue for fiscal 2025 was $88.5 million, a 24% increase [13] - Lung diagnostics revenue for Q4 2025 was $25.1 million, up 46% year-over-year, and $79.2 million for fiscal 2025, a 22% increase [13] - Adjusted EBITDA for Q4 2025 was positive at $530,000, marking the company's first positive adjusted EBITDA quarter, an improvement of 113% over Q4 2024 [17] - Gross margin for Q4 2025 was 83%, a 400 basis point improvement, while the fiscal 2025 gross margin was 81%, a 300 basis point improvement [15] Business Line Data and Key Metrics Changes - Test volumes for lung diagnostics were 18,000 in Q4 2025, a 23% increase, and 62,600 for fiscal 2025, a 15% increase [13] - Average revenue per test increased due to advancements in reimbursement and improved claims collection, contributing to the overall revenue growth [15][17] - Development services revenue for Q4 2025 was $3.6 million, a 12% increase, and $9.3 million for fiscal 2025, a 41% increase [14] Market Data and Key Metrics Changes - Volumes from primary care accounted for 12% of total Nodify tests in Q4 2025, growing 67% year-over-year, while volumes from pulmonology grew 26% [6] - The company expanded its sales strategy into primary care, accessing the remaining 50% of the nodule market managed by primary care physicians [6] Company Strategy and Development Direction - The company is focused on three main goals for 2025 and 2026: growing top-line revenue, improving organizational effectiveness, and advancing its product pipeline [3] - The strategy includes a three-tiered approach to lung nodule management, enhancing the value of Nodify Lung testing [4][6] - Partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories were announced to develop and validate tests, showcasing the company's capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute against long-term opportunities, emphasizing operational discipline and capital efficiency [21][22] - Guidance for 2026 anticipates annual revenue between $106 million and $112 million, representing a 23% growth over 2025 [19] Other Important Information - The company ended Q4 2025 with $19.0 million in unrestricted cash, a 14% increase over the previous quarter, and raised an additional $14.7 million in at-the-market proceeds [18] - The company plans to add approximately six sales representatives per quarter in 2026 to enhance market penetration [16] Q&A Session Summary Question: Expected revenue and volume step down in Q1 - Management acknowledged weather disruptions and noted that Q1 typically sees a step down in average selling price and volume, consistent with historical seasonality [26][27] Question: Pipeline developments and future tests - Management indicated that no new tests would be commercialized within the next 12 months, focusing on profitability and reimbursement timing [30] Question: Primary care sales rep productivity - The primary care focus has grown to 12% of total Nodify orders, with expectations for continued growth as the sales team matures [33] Question: Cash position and need for additional cushion - Management expressed confidence in the cash position, strengthened by operational improvements and additional cash raised [41] Question: Evidence of shifting stage in lung cancer diagnosis - Management encouraged physicians to publish data on the positive impact of Nodify testing, emphasizing the importance of awareness and compliance [46] Question: Updates on clinical studies and data readouts - Management plans to continue submitting data from the CLARIFY study and indicated that ALTITUDE data will not be available until 2027 [52]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $28.8 million, representing a 41% increase year-over-year, while total revenue for fiscal 2025 was $88.5 million, up 24% from the previous year [12] - Lung diagnostics revenue reached $25.1 million in Q4 2025, a 46% increase year-over-year, and $79.2 million for the fiscal year, a 22% increase [12] - Adjusted EBITDA for Q4 2025 was positive at $530,000, marking the company's first positive Adjusted EBITDA quarter, an improvement of 113% over Q4 2024 [17] - Gross margin improved to 83% in Q4 2025, a 400 basis point increase, and 81% for the fiscal year, a 300 basis point improvement [15] Business Line Data and Key Metrics Changes - Test volumes for lung diagnostics were 18,000 in Q4 2025, a 23% increase, and 62,600 for the fiscal year, a 15% increase [12] - Average revenue per test increased due to advancements in reimbursement and improved claims collection, contributing to the overall revenue growth [12][15] - Development services revenue was $3.6 million for Q4 2025, a 12% increase, and $9.3 million for the fiscal year, a 41% increase [13] Market Data and Key Metrics Changes - Volumes from primary care accounted for 12% of total Nodify tests in Q4 2025, growing 67% year-over-year, while volumes from pulmonology grew 26% [5] - The company expanded its sales strategy into primary care, accessing an additional 50% of the available nodule market [5] Company Strategy and Development Direction - The company is focused on three main goals: growing top-line revenue, improving organizational effectiveness, and advancing its pipeline for future growth [3] - A three-tiered commercial strategy has been implemented to enhance lung nodule management through the use of Nodify Lung testing [4] - Partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories have been established to develop and validate tests, showcasing the company's capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute against significant long-term opportunities, emphasizing operational discipline and capital efficiency [21] - Guidance for 2026 anticipates annual revenue between $106 million and $112 million, representing a 23% growth over 2025 [19] - The company acknowledged potential challenges from weather events and historical seasonality in Q1, which have been factored into the guidance [19] Other Important Information - The company ended Q4 2025 with $19.0 million in unrestricted cash, a 14% increase over the previous quarter, and raised an additional $14.7 million in at-the-market proceeds [18] - The company plans to add approximately 6 sales representatives per quarter in 2026 to enhance market penetration [16] Q&A Session Summary Question: Expected revenue and volume step down in Q1 - Management acknowledged weather disruptions and noted that Q1 typically sees a step down in average selling price and volume, consistent with historical seasonality [24][26] Question: Pipeline developments and future tests - Management indicated that no new tests are planned for commercialization within the next 12 months, focusing instead on reimbursement timing and appropriate studies [28] Question: Performance of primary care sales representatives - Primary care sales representatives accounted for 12% of total Nodify orders, with expectations for continued growth as the sales team matures [32] Question: Cash position and need for additional cushion - Management expressed confidence in the current cash position, highlighting operational improvements and the strength of the balance sheet [40] Question: Evidence of shifting stage in lung cancer diagnosis - Management encouraged physicians to publish data on the positive impact of Nodify testing, emphasizing the importance of awareness and compliance [46] Question: Updates on clinical studies and data readouts - Management confirmed ongoing efforts to publish real-world data from the CLARIFY study and noted that data from the ALTITUDE study will not be available until 2027 [52][53]

Core Insights - Biodesix, Inc. is set to present preliminary data from the CLARIFY study at the 2025 CHEST Annual Meeting, focusing on lung nodule management and the performance of Nodify tests [1][2]. Group 1: CLARIFY Study Overview - The CLARIFY study aims to validate the performance of Nodify CDT and Nodify XL2 tests through a retrospective chart review of up to 4,000 patients, with a focus on diverse patient subgroups [2]. - The study began patient enrollment shortly after the 2024 CHEST Annual Meeting and has already enrolled 1,000 patients for interim analysis [2]. Group 2: Presentations at CHEST Annual Meeting - A national analysis on lung nodule management will be presented, emphasizing the need for structured approaches to optimize healthcare resource utilization and improve patient outcomes [3]. - Multiple independent presentations will highlight the clinical value of Nodify Lung tests in various real-world patient populations [3]. Group 3: Additional Presentations - Specific presentations include comparisons of the Nodify XL2 test with PET/CT for evaluating malignancy in pulmonary nodules and the impact of Nodify Lung Test strategy in risk stratification [4]. - Other topics include the association of lung cancer screening with proteomic testing in minority communities and retrospective analyses of Biodesix biomarkers [4]. Group 4: Company Vision and Market Context - Biodesix emphasizes the transformative potential of biomarkers in lung diagnostics, coinciding with Lung Cancer Awareness Month starting November 1 [5]. - The company is dedicated to improving clinical care and outcomes for patients with lung disease through its diagnostic tests and development services [5].